Additionally, these findings not only provide new insights into CD99 implicated in apoptosis of T-ALL, but also indicate that the anti-CD99 mAb clone MT99/3 may be another candidate antibody for development of therapeutic antibody for T-ALL therapy. The gene discussed is CD99; the disease is acute lymphoblastic leukemia.